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Myocarditis and pericarditis may share common etio-logic agents, either infectious (mainly cardiotropic 
viruses) or noninfectious (ie, immune mediated such as 
systemic inflammatory diseases, vaccine-related).1,2 Thus, 
in clinical practice, a spectrum of myopericardial syn-
dromes can be encountered, ranging from pure pericarditis 
to increasing degrees of inflammatory myocardial involve-
ment (myopericarditis and perimyocarditis) to pure myo-
carditis.1–4 The term myopericarditis has been designated 
to indicate a primarily pericarditic syndrome, whereas peri-
myocarditis refers to a primarily myocarditic syndrome.1,2 
However, in the literature, these terms are often confused 
and used interchangeably.
Clinical Perspective on p 49
Despite a large amount of data published on myopericar-
ditis related to smallpox vaccination as a consequence of the 
recent US federal government vaccination program for mili-
tary forces,5–7 few data are available on the prognosis of spo-
radic cases not related to vaccination.8–11 Moreover, published 
outcome results presented contrasting data, and diagnostic 
evaluation has been heterogeneous (eg, based on simple clini-
cal criteria and troponin elevation) and did not rely on the con-
firmatory findings of cardiac magnetic resonance (CMR).8–11
The aims of this work are to evaluate the clinical presen-
tation and outcome of acute myopericarditis/perimyocarditis 
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confirmed by CMR and to compare these features with those 
of simple acute pericarditis in a prospective, multicenter study 
including all consecutive cases of acute inflammatory peri-
cardial syndromes (acute pericarditis, myopericarditis, and 
perimyocarditis).
Methods
Participants
Between January 2007 and December 2011, all consecutive patients 
with pericardial inflammatory syndromes (acute pericarditis, myo-
pericarditis, and perimyocarditis) were prospectively enrolled in 3 
Italian referral centers for pericardial diseases (Torino, Bergamo, and 
Modena). The protocol was designed prospectively before data col-
lection. Patients with pure acute myocarditis were excluded.
All patients provided informed consent. The investigation con-
forms to the principles outlined in the Declaration of Helsinki and 
local legal requirements.
Diagnostic Criteria
A diagnosis of acute pericarditis was based on the presence of at least 
2 of the following clinical criteria: pericarditis chest pain, pericar-
dial friction rub, widespread ST-segment elevation or PR depression 
on the ECG, and new or worsening pericardial effusion.12 A clini-
cal diagnosis of myopericarditis was made in patients with a defi-
nite diagnosis of acute pericarditis and elevation of cardiac markers 
of injury (troponin I or T, creatine kinase-MB fraction) without new 
onset of focal or diffuse depressed left ventricular (LV) function by 
echocardiography or CMR.4,12 Perimyocarditis was diagnosed in 
patients with clinical criteria for acute pericarditis, elevation of car-
diac markers of injury, and evidence of new onset of focal or diffuse 
depressed LV function by echocardiography or CMR. The rationale 
for these diagnostic criteria is that pure pericardial or predominant 
pericardial inflammatory involvement is not characterized by sig-
nificant impairment of myocardial function and that, on the contrary, 
focal or diffuse abnormalities of ventricular wall motion or function 
imply a substantial myocardial inflammatory involvement.13
Myocardial inflammatory involvement was clinically suspected 
in cases of atypical ECG changes for pericarditis (ie, localized ECG 
changes, abnormal ST-segment or T-wave changes or evolution, new 
Q waves), arrhythmias, cardiac troponin elevation, or new or worsen-
ing ventricular dysfunction on echocardiography and was confirmed 
by CMR.14,15 CMR imaging included T2-weighted imaging for the 
assessment of edema, T1-weighted imaging before and after contrast 
administration for the evaluation of hyperemia, and the assessment 
of late gadolinium enhancement. CMR results were considered to be 
consistent with the diagnosis of myocardial inflammatory involve-
ment if 2 of 3 CMR techniques were positive.14,15
Diagnostic Workup
Each patient was assessed by clinical evaluation, routine blood chem-
istry (including blood count, markers of inflammation and myocardial 
lesion, creatinine, transaminases), and additional tests aimed at the 
identification of the origin of disease based on the presentation fea-
tures. All patients were submitted to echocardiography at presenta-
tion. CMR was performed within 2 weeks from symptom onset when 
myocardial inflammatory involvement was suspected. Pericardial 
effusion was assessed in a semiquantitative way by 2-dimensional 
echocardiography as mild (echo-free space of <10 mm during dias-
tole), moderate (10–20 mm), and large (>20 mm). To facilitate the 
correct definition of the effusion size and to allow follow-up studies, 
the largest size, the site, and the view were recorded.12
Cardiac tamponade was diagnosed by the combination of clinical 
features (pulsus paradoxus, elevated jugular venous pressure, and 
tachycardia) and echocardiographic data (pericardial effusion with 
echocardiographic signs of tamponade).
Coronary artery disease was excluded in patients with coronary 
risk factors or dubious presentation with a need for differential 
diagnosis with acute coronary syndromes by means of coronary angi-
ography at initial presentation. Subsequent CMR was also used to 
rule out possible cases of acute myocardial infarction necrosis but 
without significant coronary artery disease.16
Histopathological confirmation of the presence of concomitant 
inflammatory myocardial involvement requires an endomyocar-
dial biopsy (EMB), but this is usually not performed in patients 
with no or mild LV systolic dysfunction and no symptoms of 
heart failure according to the indications for EMB issued by the 
American Heart Association/American College of Cardiology/
European Society of Cardiology in a scientific statement.17 In 
this study, the following indications were considered for EMB: 
subacute or acute symptoms of heart failure refractory to stan-
dard management, substantial worsening of the ejection fraction 
despite optimized pharmacological treatment, development of 
hemodynamically significant arrhythmias, heart failure with con-
current rash, fever or peripheral eosinophilia, history of collagen 
vascular disease, or suspicion of possible giant-cell myocarditis 
(young age, new subacute heart failure, or progressive arrhythmias 
without an apparent cause).
Treatment
Aspirin or a nonsteroidal anti-inflammatory drug, generally ibu-
profen, was considered the mainstay of treatment in patients with 
an established diagnosis of acute pericarditis or myopericarditis/
perimyocarditis. Aspirin was the first-choice drug and was given 
at a dose of 750 to 1000 mg orally every 6 or 8 hours for 7 to 10 
days with gradual tapering over 2 to 3 weeks. Ibuprofen was pre-
scribed at the attack dose of 600 mg 3 times a day and then tapered 
in 2 to 3 weeks. In animal models of myocarditis, nonsteroidal anti-
inflammatory drugs are not effective and may actually enhance the 
myocarditic process and increase mortality.18,19 Thus, reducing the 
dose of aspirin to 500 mg every 8 to 12 hours was considered for 
patients with myopericarditis/perimyocarditis.4 Corticosteroids were 
considered the second choice for patients with contraindications to 
or intolerance of aspirin and nonsteroidal anti-inflammatory drugs. 
In every case, gastroprotection with a proton pump inhibitor was pre-
scribed. Colchicine use (0.5 mg twice daily for 3 months or 0.5 mg 
once daily in patients <70 kg) was optional for patients with pure 
acute pericarditis and was limited in patients with myopericarditis 
and perimyocarditis because of the lack of clinical trials or studies to 
support this indication.20
Clinical Measures and Follow-Up
The relative frequency of myopericarditis/perimyocarditis was 
assessed among patients with acute pericardial inflammatory syn-
dromes. Main clinical characteristics and treatments were recorded 
for all cases. During follow-up, clinical evaluation, ECG, and rou-
tine blood chemistry were performed at 1, 6, and 12 months and 
then every year if the course was uncomplicated. Treadmill test-
ing was performed at 6 months for patients with myopericarditis/ 
perimyocarditis. All adverse events were recorded, including 
recurrent pain, relapses (either of pericarditis or other inflammatory 
myopericardial syndrome), cardiac tamponade, constrictive pericar-
ditis, residual LV dysfunction, heart failure, and overall and cardio-
vascular mortality.
Statistical Analysis
Continuous data are reported as mean±SD. Patients groups were 
compared by use of the t test for continuous variables and χ2 analysis 
for categorical variables. Time to event distributions were estimated 
with the Kaplan-Meier method and compared by use of the log-rank 
test. A value of P<0.05 was considered to show statistical signifi-
cance. Analyses were performed with SPSS version 13.0 (SPSS, 
Chicago, IL).
The authors had full access to and take full responsibility for the 
integrity of the data. All authors have read and agree to the manu-
script as written.
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Results
During the study period, 486 cases of inflammatory myo-
pericardial syndromes were recorded (346 cases of acute 
pericarditis, 114 cases of myopericarditis, and 26 cases of 
perimyocarditis; Figure 1).
Clinical Presentation and Baseline Features
Detailed baseline features are reported in Table 1. Patients 
with inflammatory myocardial involvement were younger 
and more frequently were male compared with those with 
acute pericarditis (P<0.001). Moreover, the following fea-
tures were more commonly associated with acute peri-
carditis: pericardial rubs on physical examination and 
pericardial effusion on echocardiography (P<0.01 for both). 
On the contrary, heart failure signs and symptoms and car-
diac arrhythmias were recorded with increasing frequency 
in patients with myocardial inflammatory involvement 
( myopericarditis/perimyocarditis). Left ventricular ejection 
fraction was only mildly reduced in patients with perimyo-
carditis (44±9%). White blood cells and C-reactive protein 
elevations were more common in patients with acute peri-
carditis than in patients with myopericarditis and perimyo-
carditis (P<0.001), whereas markers of myocardial lesions 
(cardiac troponin I and creatine kinase-MB) were overlap-
ping in patients with myopericarditis and perimyocarditis. 
CMR was performed in 255 cases: all patients with tropo-
nin elevation (n=140) and patients with a clinical suspicion 
of inflammatory myocardial involvement on the basis of 
clinical presentation (atypical ECG changes for pericardi-
tis, arrhythmias, and cardiac troponin elevation or new or 
worsening ventricular dysfunction on echocardiography). 
CMR data on myocardial involvement included edema 
(T2-weighted imaging)/hyperemia in 93.0% of patients with 
myopericarditis and 92.3% of patients with perimyocarditis; 
late gadolinium enhancement was detected in all cases. In 
patients with a final diagnosis of pericarditis who had CMR 
performed for a clinical suspicion of myocardial involve-
ment (n=115), pericardial abnormal T2-weighted imaging 
(edema and hyperemia) and late gadolinium enhancement 
were recorded in 104 of 115 patients (90.4%).
The initial presentation mimicked a ST-segment–elevation 
myocardial infarction in 87 of 114 patients (76.3%) with myo-
pericarditis, in 20 of 26 patients (76.9%) with perimyocarditis, 
and in only 8 of 346 patients (2.3%; P<0.001) with simple 
acute pericarditis. All these patients underwent coronary angi-
ography that excluded the presence of significant coronary 
artery disease. Acute myocardial infarction in the absence 
of significant coronary artery disease was also excluded by 
CMR.
The origin of disease (Table 2) was similar in different myo-
pericardial subgroups (idiopathic in 84%–85%, infectious in 
4%–5%, and connective tissue disease or inflammatory bowel 
disease in 10%–12%).
Patient Management
Aspirin or ibuprofen was prescribed as anti-inflammatory 
therapy in 95% of patients with acute pericarditis, 89% 
of those with myopericarditis, and 18% of patients with 
perimyocarditis. Corticosteroids were prescribed in 6% 
of patients with acute pericarditis and 4 to 6% of patients 
with myopericarditis/perimyocarditis. Colchicine was 
added to anti-inflammatory therapies in 55% of patients 
with acute pericarditis, 18% of patients with myopericar-
ditis, and 15% of those with perimyocarditis. In patients 
with myocardial inflammatory involvement, a β-blocker 
(bisoprolol 1.25 mg and then increased to reach a heart rate 
of 55–60 bpm at rest) was prescribed in 49% to 77% of 
patients, and an angiotensin-converting enzyme inhibitor 
(ramipril 1.25 mg as the starting dose and then uptitrated 
as tolerated) was prescribed in 25% to 58% of patients 
with myopericarditis/perimyocarditis with evidence of LV 
dysfunction (Table 2). Patients with a clinical diagnosis of 
myopericardial inflammatory syndromes were temporarily 
excluded from competitive, amateur, or leisure-time sport 
activity. This recommendation was independent of age, sex, 
degree of symptom, and concurrent medical therapy. After 
Figure 1. Study population of pericardial 
inflammatory syndromes. LV indicates 
left ventricular.
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resolution of the clinical picture (at least 3 months after 
the onset of the disease for simple acute pericarditis and 
6 months for those with myopericarditis/perimyocarditis), 
clinical reassessment was performed before the patients 
resumed physical activity beyond sedentary life and com-
petitive sports.21–23
Outcome and Follow-Up Data
After a median follow-up of 36 months (range, 6–66 months), 
no cases of deaths or heart failure were recorded (Table 3). 
A residual mild LV dysfunction was recorded in 8% of the 
patients with myopericarditis and 15% of the patients with 
perimyocarditis (P<0.001). An increase in mean LV ejec-
tion fraction was recorded in all subgroups at 12 months 
(Figure 2).
Recurrences were more common in acute pericarditis 
(31.8%) than in myopericarditis (10.5%) or perimyocardi-
tis (11.5%; P<0.001). In >95%, recurrences of pericarditis 
and myopericarditis/perimyocarditis were manifested as 
relapses of pericarditis and only rarely as myopericarditis 
or perimyocarditis in patients with either previous simple 
pericarditis or myopericarditis/perimyocarditis. Recurrence-
free survival was similar in patients with myopericarditis and 
perimyocarditis (Figure 3). No cases of cardiac tamponade 
Table 1. Demographics and Clinical Presentation of Patients With Inflammatory Myopericardial Syndromes
Feature
Pericarditis
(n=346)
Myopericarditis
(n=114)
Perimyocarditis
(n=26) P Value*
Age, median (IQR), y 41.0 (22.0) 29.0 (14.5) 24.0 (17.3) <0.001
Male sex, n (%) 189 (54.6) 89 (78.1) 22 (84.6) <0.001
Recent febrile syndrome, n (%) 237 (68.5) 69 (60.5) 18 (69.2) 0.212
Chest pain, n (%) 336 (97.1) 112 (98.2) 23 (88.5) 0.909
Pericardial rub, n (%) 83 (24.0) 15 (13.2) 2 (7.7) 0.005
ECG changes, n (%) 190 (55.0) 100 (88.2) 20 (76.9) <0.001
Supraventricular arrhythmias, n (%) 20 (5.8) 10 (8.8) 5 (19.2) 0.09
Ventricular arrhythmias, n (%) 1 (0.3) 5 (4.4) 2 (7.7) <0.001
Pericardial effusion, n (%) 254 (73.4) 30 (26.3) 10 (38.5) <0.001
AV block, n (%) 0 (0.0) 0 (0.0) 0 (0.0) NS
HF symptoms/signs, n (%) 0 (0.0) 4 (3.5) 3 (11.5) <0.001
EF, mean (SD), % 58.9±3.6 58.1±4.2 44.0±9.0 By definition
WBC elevation, n (%) 249 (72.0) 31 (27.1) 6 (23.1) <0.001
CRP, mg/dL 7.7±4.7 5.3±4.6 3.2±2.1 <0.001
cTnI, ng/mL† 0.0 (0.0–0.0) 7.2 (0.5–34.7) 9.4 (0.5–44.0) By definition
CK-MB, ng/mL† 0.0 (0.0–0.0) 24.0 (12–52) 34.2 (17–83) By definition
AV indicates atrioventricular; CK-MB, creatine kinase-MB; CRP, C-reactive protein; cTnI, cardiac troponin I; ECG changes, ST-segment elevation or PR depression; EF, 
ejection fraction; HF, heart failure; IRQ, interquartile range; and WBC, white blood cell.
*Comparison of acute pericarditis with myopericarditis and perimyocarditis.
†Median (range).
Table 2. Causes and Treatments of Different Inflammatory Myopericardial Syndromes
Feature
Pericarditis
(n=346), n (%)
Myopericarditis
(n=114), n (%)
Perimyocarditis
(n=26), n (%)
All
(n=486), n (%)
Idiopathic* 294 (85.0) 96 (84.2) 22 (84.6) 412 (84.8)
Infectious† 16 (4.6) 5 (4.4) 1 (3.9) 22 (4.5)
Connective tissue disease/ 
inflammatory bowel disease
36 (10.4) 13 (11.4) 3 (11.5) 52 (10.7)
Aspirin/NSAID 327 (94.5) 101 (88.6) 5 (17.6) 433 (89.1)
Corticosteroids 19 (5.5) 7 (6.1) 1 (3.8) 27 (5.6)
Colchicine 191 (55.2) 21 (18.4) 4 (15.4) 216 (44.4)
β-Blockers 2 (0.6) 56 (49.1) 20 (76.9) 78 (16.1)
ACE inhibitor 2 (0.6) 28 (24.6) 15 (57.7) 45 (9.3)
ACE indicates angiotensin-converting enzyme; and NSAID, nonsteroidal anti-inflammatory drug. 
*Without a known specific origin after diagnostic workup.
†Including known viral and bacterial (tuberculosis) causes. Detailed infectious causes included the following: pericarditis: coxsackievirus in 4 cases (25.0%), Epstein-
Barr virus in 3 cases (18.75%), parvovirus in 3 cases (18.75%), adenovirus in 3 cases (18.75%), cytomegalovirus in 2 cases (12.5%), and influenza in 1 case (6.25%); 
myopericarditis: coxsackievirus in 3 cases (60.0%) and parvovirus in 2 cases (40.0%); and perimyocarditis: parvovirus in 1 case (100%). Percentages are reported 
according to diagnosed infectious cases in each group: acute pericarditis, myopericarditis, and perimyocarditis.
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were recorded in patients with myopericarditis and perimyo-
carditis, and 1 case of constrictive pericarditis was recorded 
in patients with myopericarditis. Troponin elevation was 
not associated with an increase in complications during 
follow-up.
Discussion
Relative Frequency of Myopericarditis/
Perimyocarditis
This prospective cohort study provides evidence for the first 
time of the relative frequency of myopericardial inflammatory 
syndromes in adults. Myocardial involvement is relatively fre-
quent and was recorded in one third of patients with acute 
pericardial inflammatory syndromes. Myopericarditis is more 
frequent than perimyocarditis (23.5% versus 5.4%, respec-
tively, of all patients with acute pericardial inflammatory syn-
dromes; P<0.001).
Peculiar Features of Myopericarditis/
Perimyocarditis
Patients with myocardial involvement are younger than those 
with simple acute pericarditis; moreover, more patients with 
myopericarditis/perimyocarditis are male, as already reported 
in previous reports,4,9–11 which suggests the possibility that 
hormonal factors may play a role in the etiopathogenesis of 
myopericardial inflammatory syndromes.
This study also underlines specific peculiarities of the 
clinical presentation. The presence of pericardial rubs and 
pericardial effusion is usually associated with less myocar-
dial involvement, whereas the presence of ST and PR abnor-
malities suggests an increased likelihood of myocardial 
involvement.
ST-segment elevation or PR depression, usually consid-
ered hallmarks of acute pericarditis, can be recorded in only 
50% to 60% of patients with simple acute pericarditis. These 
ECG changes reflect the extent of subepicardial involve-
ment because the pericardium is electrically silent, and they 
are especially suggestive of concomitant myocardial inflam-
matory involvement rather than simple acute pericarditis. 
Myocardial involvement is often associated with ST-segment 
elevation (>75% of cases), with an initial presentation that 
may simulate an acute coronary syndrome in a substantial 
number of patients (≈75%). In addition, arrhythmias are pecu-
liar of myocardial inflammatory involvement and should alert 
Table 3. Follow-Up Data
Feature
Pericarditis
(n=346), n (%)
Myopericarditis
(n=114), n (%)
Perimyocarditis
(n=26), n (%) P Value*
Recurrence 110 (31.8) 12 (10.5) 3 (11.5) <0.001
Cardiac tamponade 8 (2.3) 0 (0.0) 0 (0.0) NS
Constrictive pericarditis 2 (0.6) 1 (0.9) 0 (0.0) NS
Heart failure 0 (0.0) 0 (0.0) 0 (0.0) NS
LV dysfunction (EF <55%) at 12 mo 4 (1.1) 9 (7.9) 4 (15.4) <0.001
All-cause death 0 (0.0) 0 (0.0) 0 (0.0) NS
EF indicates ejection fraction; and LV, left ventricular. Median follow-up was 36 months (range, 6 to 88 months). Recurrences were manifested as recurrent 
pericarditis in >90% of cases.
*Comparison of acute pericarditis with myopericarditis and perimyocarditis.
Figure 2. Evolution of mean values of 
left ventricular ejection fraction (LVEF) 
in study subgroups from baseline to 12 
months. Values are mean±SD.
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the clinician when recorded in a patient with presumed acute 
pericarditis.
Another significant issue is related to biomarker expression 
in different types of inflammatory myopericardial syndromes. 
Elevation of C-reactive protein is recorded in all subgroups, 
but higher levels are found in patients with simple pericarditis 
compared with those with myopericarditis/perimyocarditis. 
Cardiac troponin elevation is roughly related to the extent of 
myocardial involvement (median, 9.4 ng/mL; range, 1.0–44.0 
ng/mL in perimyocarditis; median, 7.2 ng/mL; range, 1.0–
34.7 ng/mL in myopericarditis) and was largely overlapping 
in the 2 syndromes.
Origin and Therapeutic Issues
The origin is similar in different subgroups, regardless of the 
entity of myocardial inflammatory involvement. Most cases 
remain idiopathic with a conventional diagnostic approach; 
these results are consistent with previously published 
data.4,10,11
Empirical anti-inflammatory therapies with aspirin or a 
nonsteroidal anti-inflammatory drug were adopted mainly 
for patients with prevalent pericardial involvement (>85% of 
cases), whereas reduced doses were considered in patients 
with perimyocarditis because of the fear of possible negative 
effects of these therapies in myocarditis. Additionally, corti-
costeroids should probably not be used in this setting as first-
line therapy; we have limited data on the use of colchicine 
because patients with myocardial involvement were excluded 
in previous clinical trials of the treatment and prevention of 
pericarditis.20
Prognostic Issues
Unlike acute coronary syndromes, cardiac troponin eleva-
tion was not a negative prognostic marker in myopericarditis/
perimyocarditis, and the degree of troponin elevation did not 
correlate with the likelihood of subsequent recovery. Most 
of these patients had a normal or nearly normal LV function 
at presentation and generally improved during a 12-month 
follow-up, with normalization of LV function in >90% of 
patients with myopericarditis and >80% of patients with peri-
myocarditis. No deaths correlated to pericardial or myocar-
dial involvement were recorded during follow-up. These data 
are reassuring and confirm preliminary findings in pediatric 
populations and adults (Table 4).4,10,11 Recurrences were more 
common with prevalent pericardial involvement and generally 
were recurrent pericarditis.
Clinical Implications
Some involvement of the myocardium should be suspected 
in any young patient with chest pain, ST-segment elevation 
at presentation, and cardiac arrhythmia (sustained or not, 
either supraventricular or ventricular; Table 1), whereas 
rubs and pericardial effusion are more suggestive of isolated 
pericardial involvement. In the setting of myopericarditis/
perimyocarditis, the differential diagnosis should especially 
include acute coronary syndromes, and up to 3 of 4 of these 
patients may have a presentation that may simulate an acute 
coronary syndrome. Coronary angiography is necessary 
to rule out and promptly treat acute myocardial infarction 
with ST-segment elevation. For patients without evidence of 
coronary artery disease or a pseudoinfarctual presentation, 
CMR is a useful noninvasive diagnostic tool for the clinical 
diagnosis of myopericardial inflammatory syndromes and 
to rule out acute myocardial infarction with normal coro-
nary arteries.16,24–28 In these cases, the diagnostic utility of 
EMB is clearly reduced for clinicians. Although EMB may 
establish a definite diagnosis, it is difficult to justify its clini-
cal utility in patients with myopericarditis/perimyocarditis 
Figure 3. Recurrence-free survival in different 
subgroups of inflammatory myopericardial 
syndromes.
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in the absence of major cardiac arrhythmias, heart failure, 
or failure of conventional therapies because treatment and 
management are not affected by the results of EMB and the 
prognosis seems benign. Moreover, recently published data 
have compared the diagnostic performance of CMR imag-
ing with EMB.29 In 132 patients with suspected acute myo-
carditis (symptoms lasting ≤14 days) or chronic myocarditis 
(defined as symptoms lasting >14 days), the overall diagnos-
tic sensitivity, specificity, and accuracy of CMR were 76%, 
54%, and 68%, respectively, and were better in the setting 
of acute disease (81%, 71%, and 79%, respectively). Thus, 
in clinical practice, CMR is useful for the noninvasive diag-
nosis of myocardial inflammatory involvement, especially 
in patients with recent symptom onset (<2 weeks) like the 
patients included in the present study.
This cohort study is reassuring in terms of the prognosis of 
myopericardial inflammatory syndromes. Patients with acute 
pericarditis and myopericarditis have a very good prognosis 
with no worsening of LV function and no recorded deaths. 
During follow-up, recurrences were the only significant 
complications and generally manifested as recurrent peri-
carditis after either acute pericarditis or myopericarditis and 
perimyocarditis.
Study Limitations
This is the first study to date to include patients with myo-
pericarditis and perimyocarditis and to emphasize the clini-
cal spectrum of myopericardial inflammatory syndromes.3 
The first limitation of the study is that the diagnosis was 
based on clinical criteria and was not confirmed by EMB 
because no patients fulfilled the indications for EMB accord-
ing to American Heart Association/American College of 
Cardiology/European Society of Cardiology guidelines.17 
However, there is now good and growing evidence to sup-
port the use of CMR as a noninvasive diagnostic tool for 
clinicians,29 especially when additional invasive tools do not 
affect the subsequent therapy and management of patients. 
The second and third limitations are related to the length of 
our follow-up and the subgroup sample size. Longer follow-
up and larger populations are needed to confirm the benign 
outcome, although this study includes the largest published 
group of patients with inflammatory myopericardial syn-
dromes to date.
Conclusions
Myopericardial inflammatory syndromes (myopericardi-
tis/perimyocarditis) are benign clinical syndromes that can 
frequently be encountered in patients with an initial suspi-
cion of pericarditis. The main differential diagnosis is with 
ST-segment–elevation myocardial infarction, and coronary 
angiography may be required. CMR is a useful diagnostic tool 
for the noninvasive diagnosis of concomitant myopericardial 
inflammatory involvement and may help to distinguish these 
syndromes from myocardial infarction.
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CLINICAL PERSPECTIvE
A group of 486 patients with inflammatory myopericardial syndromes (pericarditis, myopericarditis, and perimyocarditis) 
were followed up for a median follow-up of 36 months. Myocardial involvement was relatively frequent and recorded in one 
third of patients. Myopericarditis was defined as pericarditis and elevation of cardiac markers of injury without new onset of 
focal or diffuse depressed left ventricular function by echocardiography or cardiac magnetic resonance; perimyocarditis was 
diagnosed as pericarditis plus elevation of cardiac markers of injury and evidence of new onset of focal or diffuse depressed 
left ventricular function by echocardiography or cardiac magnetic resonance. Myocardial inflammatory involvement was 
confirmed by cardiac magnetic resonance. Clinical clues of myocardial involvement included ST-segment elevation (>75% 
of cases), arrhythmias, and troponin elevation, which was roughly related to the extent of myocardial involvement but largely 
overlapping in myopericarditis/perimyocarditis. Unlike acute coronary syndromes, cardiac troponin elevation was not a 
negative prognostic marker in myopericarditis/perimyocarditis, and the degree of troponin elevation did not correlate with 
the likelihood of subsequent recovery. In the setting of myopericarditis/perimyocarditis, the differential diagnosis should 
especially include acute coronary syndromes, and the presentation in up to 3 of 4 of these patients may simulate an acute 
coronary syndrome. Left ventricular function was normalized in 90% of the patients. No deaths correlated to pericardial or 
myocardial involvement were recorded during follow-up. Recurrences generally manifested as recurrent pericarditis and 
were more common with simple pericarditis. Cardiac magnetic resonance is a useful diagnostic tool for the noninvasive 
diagnosis of concomitant myocardial inflammatory involvement.
Go to http://cme.ahajournals.org to take the CME quiz for this article.
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